Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Rises By 223.2%

GlucoTrack, Inc. (NASDAQ:GCTK) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totaling 2,166,796 shares, an increase of 223.2% from the April 15th total of 670,479 shares. Based on an average daily trading volume, of 9,640,460 shares, the days-to-cover ratio is presently 0.2 days. Currently, 114.0% of the shares of the company are sold short.

GlucoTrack Stock Performance

GCTK stock traded down $0.03 during trading on Thursday, reaching $0.67. 340,432 shares of the stock were exchanged, compared to its average volume of 10,959,795. GlucoTrack has a twelve month low of $0.58 and a twelve month high of $15.90. The company has a market capitalization of $1.30 million, a P/E ratio of -0.01 and a beta of 0.78. The stock has a 50 day simple moving average of $0.93 and a 200-day simple moving average of $2.99. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.08.

GlucoTrack (NASDAQ:GCTK) last issued its earnings results on Thursday, May 14th. The company reported $2.65 earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of GlucoTrack

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of GlucoTrack by 102,125.0% during the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after acquiring an additional 4,085 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of GlucoTrack during the 4th quarter valued at about $52,000. Finally, Ikarian Capital LLC acquired a new stake in shares of GlucoTrack during the 4th quarter valued at about $177,000. 10.92% of the stock is currently owned by institutional investors and hedge funds.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.